BIAF SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

bioAffinity Technologies Reports Third Quarter 2026 Results and Commercial Momentum for CyPath Lung

Nov 6, 2026

8-K

bioAffinity Technologies to Highlight CyPath Lung Test at North Carolina Lung Cancer Awareness Event

Oct 29, 2026

8-K

bioAffinity Technologies to Present New Perspectives on CyPath® Lung at CHEST 2026

Oct 15, 2026

8-K

bioAffinity Technologies to Present Positive Research Data at CHEST 2026 for New Test Measuring Asthma and COPD-Related Lung Inflammation

Oct 13, 2026

8-K

bioAffinity Technologies Announces Approximately $4 Million Registered Direct Financing and Concurrent Private Placement

Oct 9, 2026

8-K

bioAffinity Technologies Announces Notice of Allowance from Japan Patent Office for CyPath® Lung Test

Oct 8, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

November 2026 ATM | Offering amount: $5,228,226 | Bank: WallachBeth Capital LLC

Nov 3, 2026

424B5

AMENDED - November 2026 ATM | Offering amount: $5,228,226 | Bank: WallachBeth Capital LLC

Nov 2, 2026

424B5

REGISTERED OFFERING

Oct 9, 2026

424B5

AMENDED - October 2026 ATM | Bank: WallachBeth Capital LLC

Oct 9, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 1,692,408

Sep 8, 2026

424B4

FIXED PRICE OFFERING | Offering amount: $3,200,000 | Shares: 4,000,000 | Price: $0.800 | Bank: WallachBeth Capital LLC

Jun 18, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-3/A

SHARE RESALE REGISTRATION

Sep 3, 2026

S-3

SHARE RESALE REGISTRATION

Aug 27, 2026

S-1/A

OFFERING | Bank: WallachBeth Capital LLC

Jun 16, 2026

S-1

OFFERING (Best Efforts Basis) - WallachBeth Capital LLC

Jun 12, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 20, 2026

DRS

Form DRS - Draft Registration Statement

Apr 30, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 23, 2026

PRER14A

Form PRER14A - Preliminary Proxy Soliciting materials

Oct 13, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Sep 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 16, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 5, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Nov 12, 2025

Ownerships

TYPE

HEADLINE

FILED AT

S-3/A

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Sep 3, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Aug 27, 2026

SCHEDULE 13G

BIGGER CAPITAL FUND L P (Filed by)

Oct 1, 2025

Rios Roberto (Reporting)

Sep 25, 2025

Oppenheimer John J. (Reporting)

Sep 25, 2025

SCHEDULE 13G

Crumly Richard K. (Filed by)

May 14, 2025

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 8, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 17, 2026

CORRESP

Form CORRESP - Correspondence

Jun 12, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

May 13, 2026

CORRESP

Form CORRESP - Correspondence

May 11, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 7, 2026

bioAffinity Technologies, Inc. BIAF · SEC Filings